1. Home
  2. TAYD vs CHRS Comparison

TAYD vs CHRS Comparison

Compare TAYD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taylor Devices Inc.

TAYD

Taylor Devices Inc.

HOLD

Current Price

$62.10

Market Cap

165.2M

Sector

Industrials

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.29

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAYD
CHRS
Founded
1955
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.2M
177.7M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
TAYD
CHRS
Price
$62.10
$1.29
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$70.00
$5.51
AVG Volume (30 Days)
31.1K
898.4K
Earning Date
03-31-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
2.62
N/A
Revenue
$41,649,673.00
N/A
Revenue This Year
$0.25
$73.08
Revenue Next Year
$19.78
$30.94
P/E Ratio
$23.09
N/A
Revenue Growth
N/A
N/A
52 Week Low
$40.50
$1.09
52 Week High
$90.37
$2.62

Technical Indicators

Market Signals
Indicator
TAYD
CHRS
Relative Strength Index (RSI) 57.61 48.85
Support Level $57.54 $1.33
Resistance Level $62.30 $1.51
Average True Range (ATR) 1.79 0.08
MACD -0.15 -0.00
Stochastic Oscillator 52.28 59.37

Price Performance

Historical Comparison
TAYD
CHRS

About TAYD Taylor Devices Inc.

Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: